文献速递糖尿病

酶法2-羟基丁酸检测用于常规空腹指标之外的血糖异常筛查

Enzymatic 2-Hydroxybutyrate Measurement for Dysglycemia Screening Beyond Conventional Fasting Measures.
PubMed 文献 · Diabetes Care · 2026-01-01

研究在772人的Biomarkers of Personalized Medicine队列中评估新型酶法(XpressGT)检测的空腹2-羟基丁酸(2-HB)能否在常规空腹指标之外提供血糖异常的增量判别。在534例空腹血糖和HbA1c正常者中,2-HB对餐后血糖异常的AUC为0.79,39 µmol/L时敏感性90%、阴性预测值98.9%。结论认为酶法2-HB可作为排除空腹血糖和HbA1c正常者餐后血糖异常的筛查标志物。

要点

  • 2-HB从正常血糖39.0 µmol/L升至糖尿病前期51.9 µmol/L和2型糖尿病57.0 µmol/L。
  • 空腹血糖<110 mg/dL且HbA1c<5.7%者中,2-HB筛查餐后血糖异常AUC为0.79。
  • 39 µmol/L时敏感性90%、阴性预测值98.9%,2-HB每增1个标准差与血糖异常独立相关(OR 2.23,P<0.001)。

核心结论

  • 酶法2-HB检测可能作为筛查标志物,用于排除空腹血糖和HbA1c正常者的餐后血糖异常。

研究设计与样本

  • 在Biomarkers of Personalized Medicine总队列及预设亚组(空腹血糖<110 mg/dL且HbA1c<39 mmol/mol即5.7%)中评估2-HB与血糖异常的关联。
  • 共纳入772人,其中534人空腹血糖和HbA1c正常。

主要发现

  • 2-HB从正常血糖39.0 µmol/L升至糖尿病前期51.9 µmol/L和2型糖尿病57.0 µmol/L。
  • 534例空腹血糖和HbA1c正常者中,2-HB对餐后血糖异常(口服葡萄糖耐量试验2小时血糖>140 mg/dL)的AUC为0.79。
  • 39 µmol/L时敏感性达90%,阴性预测值为98.9%。
  • 2-HB每增加1个标准差与血糖异常独立相关(OR 2.23;P<0.001)。

临床怎么用

  • 对空腹血糖和HbA1c正常者,可考虑用酶法2-HB筛查以排除餐后血糖异常。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We investigated whether fasting 2-hydroxybutyrate (2-HB), measured by a novel enzymatic assay (XpressGT), can provide incremental discrimination of dysglycemia beyond routine fasting measures. RESEARCH DESIGN AND METHODS: Associations of 2-HB with dysglycemia were assessed in the total Biomarkers of Personalized Medicine cohort and in the prespecified subcohort with fasting plasma glucose (FPG) <110 mg/dL and HbA1c <39 mmol/mol (5.7%). RESULTS: Among 772 individuals, 2-HB increased from normoglycemia (39.0 µmol/L) to prediabetes (51.9 µmol/L) and type 2 diabetes (57.0 µmol/L). In 534 individuals with normal FPG and HbA1c, 2-HB yielded the area under the receiver operating characteristic curve of 0.79 for postprandial dysglycemia (2-h glucose >140 mg/dL during oral glucose tolerance testing). A sensitivity of 90% was achieved at 39 µmol/L, with a negative predictive value of 98.9%. Each 1-SD increase in 2-HB was independently associated with dysglycemia (odds ratio 2.23; P < 0.001). CONCLUSIONS: Enzymatic 2-HB measurement may serve as a screening biomarker to rule out postprandial dysglycemia in individuals with normal FPG and HbA1c.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Strohhofer C, Eberhard K, Obermayer-Pietsch B, et al. Enzymatic 2-Hydroxybutyrate Measurement for Dysglycemia Screening Beyond Conventional Fasting Measures. Diabetes Care. 2026. PMID: 42257650. doi:10.2337/dc26-0567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。